Table 1.
Demographics and baseline characteristics for the placebo, NVX-CoV2373–placebo, and NVX-CoV2373–NVX-CoV2373 groups in the safety analysis set who received three doses
| Placebo group (n=172) | NVX-CoV2373–placebo group (n=102) | NVX-CoV2373–NVX-CoV2373 group (n=105) | |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 51·9 (17·2) | 52·0 (17·0) | 51·7 (17·1) |
| Median (range) | 56·0 (18–83) | 57·5 (19–80) | 58·0 (19–82) |
| Age group | |||
| 18–59 years | 95 (55%) | 55 (54%) | 57 (54%) |
| 60–84 years | 77 (45%) | 47 (46%) | 48 (46%) |
| Sex | |||
| Male | 100 (58%) | 43 (42%) | 58 (55%) |
| Female | 72 (42%) | 59 (58%) | 47 (45%) |
| Race | |||
| White | 151 (88%) | 86 (84%) | 93 (89%) |
| Black or African American | 2 (1%) | 3 (3%) | 3 (3%) |
| Asian | 15 (9%) | 10 (10%) | 7 (7%) |
| American Indian or Alaska Native | 2 (1%) | 1 (1%) | 1 (1%) |
| Multiple | 2 (1%) | 1 (1%) | 1 (1%) |
| Missing | 0 | 1 (1%) | 0 |
| Ethnicity | |||
| Hispanic or Latino | 11 (6%) | 3 (3%) | 1 (1%) |
| Not Hispanic or Latino | 161 (94%) | 97 (95%) | 104 (99%) |
| Unknown | 0 | 2 (2%) | 0 |
| Baseline BMI, kg/m2 | |||
| Mean (SD) | 27·29 (4·207) | 26·69 (4·060) | 27·43 (4·040) |
| Median (IQR) | 27·40 (24·30–30·70) | 26·50 (24·10–29·50) | 27·10 (25·10–30·70) |
| Baseline SARS-CoV-2 status | |||
| Negative | 169 (98%) | 101 (99%) | 102 (97%) |
| Positive | 2 (1%) | 1 (1%) | 3 (3%) |
| Indeterminate | 1 (1%) | 0 | 0 |
Data are n (%), unless otherwise stated.